Ilse
Ilse Casteren Van, Waalwijk NL
Patent application number | Description | Published |
---|---|---|
20080274361 | Low Nwp Aqueous Polyurethane Composition - An aqueous composition with a sediment content ≦5%, comprising a polyurethane dispersion wherein the polyurethane has an acid value in the range of from 25 to 65 mgKOH/g and comprises (i) 36 to 60 wt % of at least one aromatic polyisocyanate and where the polyurethane is prepared in the presence of (a) ≦5 wt % of 1-methyl-2-pyrrolidinone by weight of the polyurethane, (b) 5 to 100 wt % of 1-ethyl-2-pyrrolidinone by weight of polyurethane and (c) water. | 11-06-2008 |
20110064956 | LOW NWP AQUEOUS POLYURETHANE COMPOSITION - An aqueous composition with a sediment content ≦5%, comprising a polyurethane dispersion wherein the polyurethane has an acid value in the range of from 25 to 65 mgKOH/g and comprises (i) 36 to 60 wt % of at least one aromatic polyisocyanate and where the polyurethane is prepared in the presence of (a) ≦5 wt % of 1-methyl-2-pyrrolidinone by weight of the polyurethane, (b) 5 to 100 wt % of 1-ethyl-2-pyrrolidinone by weight of polyurethane and (c) water. | 03-17-2011 |
Ilse De Canck, Antwerpen BE
Patent application number | Description | Published |
---|---|---|
20100099081 | Method for Typing HLA Alleles - The present invention relates to the typing of HLA alleles. The sequence of exon 2 and exon 3 of the alleles HLA-B*3913, HLA-B*1406 and HLA-B*51 new and of exon 2 of the alleles HLA-DRB1*0820, HLA-DRB1*04 new and HLA-DRB4*01 new are disclosed. The present invention relates to methods for typing of said alleles. According to a preferred embodiment, said typing comprises the following steps: i) amplifying a relevant fragment of said alleles using at least one suitable pair of primers; ii) hybridizing the amplification product of step i) to at least one probe that specifically hybridizes to a target region comprising one or more polymorphic nucleotides in said relevant fragment; iii) determining from the result of step ii) the absence or presence of said alleles in the sample. The present invention further provides primers and probes to be used in said methods for typing. A diagnostic kit comprising said primers and probes is also part of the present invention. | 04-22-2010 |
Ilse Gutierrez-Roelens, Glabais BE
Patent application number | Description | Published |
---|---|---|
20100273671 | METHOD FOR THE DETERMINATION AND THE CLASSIFICATION OF RHEUMATIC CONDITIONS - Methods for the determination and the classification of a rheumatic condition in a synovial sample of a subject afflicted with a rheumatic condition are disclosed. Methods include the steps of determining in the level of expression of at least 20 genes or gene fragments in the synovial sample and identifying whether the level of expression of the genes in the sample correlates with the presence of a rheumatic condition. Kits are also described for the determination and the classification of rheumatic conditions which contain a low density microarray having probes suitable for hybridizing with at least 20 genes or gene fragments. On the basis of the hybridization results, the rheumatic condition is determined. | 10-28-2010 |
Ilse Heckelmann, Kempen DE
Patent application number | Description | Published |
---|---|---|
20120279621 | STEEL, STEEL FLAT PRODUCT, STEEL PART AND METHOD FOR PRODUCING A STEEL PART - Disclosed is a steel, a steel flat product, a steel part produced from it by hot forming with subsequent hardening, and a method for producing a steel part. In order to guarantee to a high degree of reliability that a part possesses high strength values and an increased elongation at break, the steel contains (in % wt.) C: 0.15-0.40%, Mn: 1.0-2.0%, Al: 0.2-1.6%, Si: 0-1.4%, total of the contents of Si and Al: 0.25-1.6%, P: 0-0.10%, S: 0-0.03%, Cr: 0-0.5%, Mo: 0-1.0%, N: 0-0.01%, Ni: 0-2.0%, Nb: 0.012-0.04%, Ti 0-0.40%, B: 0.0010-0.0050%, Ca: 0-0.0050%, remainder iron and unavoidable impurities. | 11-08-2012 |
Ilse Hurbain, Bures FR
Patent application number | Description | Published |
---|---|---|
20110038853 | Use of Kif13A and AP-1 Inhibitors for Inhibiting Melanogenesis - The present invention relates to novel pharmaceutical or cosmetic compositions comprising at least one inhibitor of a sub-unit of AP-1 adaptor complex, of a kinesin interacting with AP-1, in particular Kif13A, or of the interaction between a sub-unit of AP-1 adaptor complex and said kinesin, as well as the use of same to manufacture a drug intended for the treatment of pigmentary disorders and as a depigmentation agent. | 02-17-2011 |
20120321575 | USE OF KIF13A AND AP-1 INHIBITORS FOR INHIBITING MELANOGENESIS - The present invention relates to novel pharmaceutical or cosmetic compositions comprising at least one inhibitor of a sub-unit of AP-1 adaptor complex, of a kinesin interacting with AP-1, in particular Kif13A, or of the interaction between a sub-unit of AP-1 adaptor complex and said kinesin, as well as the use of same to manufacture a drug intended for the treatment of pigmentary disorders and as a depigmentation agent. | 12-20-2012 |
Ilse Lange De, Hellevoetsluis NL
Patent application number | Description | Published |
---|---|---|
20100136169 | NOVEL ASPARAGINASES AND USES THEREOF - The present invention relates to an asparaginase having the width of the pH activity profile which is at least 3.5. Furthermore the invention relates to newly identified asparaginase polypeptide according to any one of SEQ ID NO: 2 or SEQ ID NO: 4 and to variants thereof and to polynucleotide sequences that encode such novel asparaginase variants. Furthermore the invention relates to the use of these novel asparaginase variants in industrial processes. | 06-03-2010 |
Ilse Loenneker, Bevern DE
Patent application number | Description | Published |
---|---|---|
20100291005 | USE OF TRANS-PELLITORIN AS FLAVOR SUBSTANCE - The invention concerns the use of 2E,4E-decadienoic acid-N-isobutylamide (trans-pellitorin) as flavorant, in particular as salivation inducing flavor substance, preferably in a foodstuff or nutrient, an oral hygienic preparation or a gourmet or snack preparation. Further, the invention concerns preparations, semi-finished preparations as well as fragrance, aroma and taste compositions, containing trans-pelletorin as well as a processes for the production of trans-pelletorin. | 11-18-2010 |
Ilse Roodink, Loenen NL
Patent application number | Description | Published |
---|---|---|
20100119445 | PLEXIN D1 AS A TARGET FOR TUMOR DIAGNOSIS AND THERAPY - The present invention relates to plexin D1 for use as a targetable protein in the treatment or diagnosis of disorders that involve expression of plexin D1. Diagnosis is suitably effected by detecting the presence of plexin D1 in the body or a bodily tissue or fluid, whereas treatment is effected by targeting plexin D1 for delivery of therapeutics to the site where treatment is needed. The invention further relates to the use of molecules that bind plexin D1, a nucleic acid encoding plexine D1 or a ligand of plexin D1 for the preparation of a therapeutical composition for the treatment or diagnosis of disorders that involve expression of plexin D1. The disorders comprise disorders in which plexin D1 is expressed on tumor cells, tumor blood vessels or activated macrophages. | 05-13-2010 |
Ilse Roodink US
Patent application number | Description | Published |
---|---|---|
20120321554 | PLEXIN D1 AS A TARGET FOR TUMOR DIAGNOSIS AND THERAPY - The present invention relates to plexin D1 for use as a targetable protein in the treatment or diagnosis of disorders that involve expression of plexin D1. Diagnosis is suitably effected by detecting the presence of plexin D1 in the body or a bodily tissue or fluid, whereas treatment is effected by targeting plexin D1 for delivery of therapeutics to the site where treatment is needed. The invention further relates to the use of molecules that bind plexin D1, a nucleic acid encoding plexine D1 or a ligand of plexin D1 for the preparation of a therapeutical composition for the treatment or diagnosis of disorders that involve expression of plexin D1. The disorders comprise disorders in which plexin D1 is expressed on tumor cells, tumor blood vessels or activated macrophages. | 12-20-2012 |
Ilse Talle, Rheine DE
Patent application number | Description | Published |
---|---|---|
20080283516 | Current Supply for Heaters - The invention relates to a current supply device for a surface resistance heater, a heating system and to a method for supplying a surface resistance heater with current. The resistance of the surface resistance heater is measured in a continuous manner in order to detect short-circuits. In the event of a short-circuit, the current is limited or cut-off. Said current supply device is, preferably, embodied as a skirting board or as a cover strip. | 11-20-2008 |
Ilse Tepas, Delft NL
Patent application number | Description | Published |
---|---|---|
20120281935 | HEATING APPARATUS, TRANSPORTATION UNIT, SYSTEM AND METHOD FOR REMOVING FOODSTUFFS - The invention relates to a transportation unit for transport of foodstuffs that are highly viscous or solid at ambient temperatures. The transportation unit comprises a first bag, a second bag arranged to fit into the first bag, and one or more hoist bands wrapped around the bottom side of the first bag and connected thereto. The first bag has an upper side and a bottom side, and is made from a woven fabric, preferably a woven polymer. Additionally, the first bag comprises a transfer opening for removing the foodstuffs from the transportation unit. The second bag comprises an opening for inserting and/or removing the foodstuffs. The second bag is capable of transporting more than 2000 kg of foodstuffs. The one or more hoist bands form loops above the upper side of the first bag. | 11-08-2012 |
Ilse Van Casteren, Waalwijk NL
Patent application number | Description | Published |
---|---|---|
20100144915 | RADIATION CURABLE AQUEOUS COMPOSITION FOR LOW GLOSS COATINGS - A radiation curable aqueous coating composition having a 85° gloss of ≦60 upon drying comprising (A) 10 to 99 wt % of a polyurethane, (B) 1 to 90 wt % of a radiation curable component; (C) 0.1 to 10 wt % of an associative thickener; wherein at least 80 wt % of (A)+(B)+(C) has a particle size greater than 500 nm and wherein the C═C bond concentration of the composition is 0.2 to 5.0 mmol per g of (A)+(B)+(C). | 06-10-2010 |
20110091653 | COATING COMPOSITION COMPRISING AUTOXIDISABLE COMPONENT - There is described (pref. non-adhesive) coating compositions (which may be either water or solvent borne) that comprise an autoxidisable vinyl polymer, the autoxidisable polymer having a vinyl polymer backbone 25% to 75% by wt of the autoxidisable polymer; fatty acid residue 25% to 75% by wt of the autoxidisable polymer; T | 04-21-2011 |
20110118394 | COATING COMPOSITION COMPRISING AUTOXIDISABLE COMPONENT - An aqueous solution coating composition comprising an autoxidisable polyvinyl polymer having ≧20% of fatty acid residue by weight of polymer; T | 05-19-2011 |
20110118407 | COATING COMPOSITION COMPRISING AUTOXIDISABLE COMPONENT - An aqueous emulsion coating composition comprising an autoxidisable vinyl oligomer having ≧20 wt % of unsaturated fatty acid residue; Tg from −50 to +15° C.; Mw from 2,500 to 40,000 g/mol; polydispersity from 2 to 12, said composition having ≦15% co-solvent by weight of solids, ≦13% NMP by weight of solids ≧38% solids by weight of composition; said composition when in the form of a coating having a telegraphing value defined as the difference in gloss at a 20° angle of between a film cast on rough PVC and a film cast on smooth PVC of 10 gloss units. | 05-19-2011 |
20120270990 | RADIATION CURABLE AQUEOUS COMPOSITION FOR LOW GLOSS COATINGS - A radiation curable aqueous coating composition having a 85° gloss of ≦60 upon drying comprising (A) 10 to 99 wt % of a polyurethane, (B) 1 to 90 wt % of a radiation curable component; (C) 0.1 to 10 wt % of an associative thickener; wherein at least 80 wt % of (A)+(B)+(C) has a particle size greater than 500 nm and wherein the C═C bond concentration of the composition is 0.2 to 5.0 mmol per g of (A)+(B)+(C). | 10-25-2012 |
20130184396 | RADIATION CURABLE AQUEOUS COMPOSITION FOR LOW GLOSS COATINGS - A radiation curable aqueous coating composition having a 85° gloss of ≦60 upon drying comprising (A) 10 to 99 wt % of a polyurethane, (B) 1 to 90 wt % of a radiation curable component; (C) 0.1 to 10 wt % of an associative thickener; wherein at least 80 wt % of (A)+(B)+(C) has a particle size greater than 500 nm and wherein the C═C bond concentration of the composition is 0.2 to 5.0 mmol per g of (A)+(B)+(C). | 07-18-2013 |
20130225724 | COATING COMPOSITION COMPRISING AUTOXIDISABLE COMPONENT - There is described (pref. non-adhesive) coating compositions (which may be either water or solvent borne) that comprise an autoxidisable vinyl polymer, the autoxidisable polymer having a vinyl polymer backbone 25% to 75% by wt of the autoxidisable polymer; fatty acid residue 25% to 75% by wt of the autoxidisable polymer; T | 08-29-2013 |
20140004351 | PROCESS FOR MAKING HIGH-PERFORMANCE POLYETHYLENE MULTIFILAMENT YARN | 01-02-2014 |
20140114010 | RADIATION CURABLE AQUEOUS COMPOSITION FOR LOW GLOSS COATINGS - A radiation curable aqueous coating composition having a 85° gloss of ≦60 upon drying comprising (A) 10 to 99 wt % of a polyurethane, (B) 1 to 90 wt % of a radiation curable component; (C) 0.1 to 10 wt % of an associative thickener; wherein at least 80 wt % of (A)+(B)+(C) has a particle size greater than 500 nm and wherein the C═C bond concentration of the composition is 0.2 to 5.0 mmol per g of (A)+(B)+(C). | 04-24-2014 |
Ilse Vanhorebeek, Lubbeek BE
Patent application number | Description | Published |
---|---|---|
20140066439 | OSTEOCLAST ACTIVITY - Described are medicaments and methods of treating or preventing metabolic bone diseases, such as Critical Illness Related Metabolic Bone Disease or of critical illness induced Osteopenia secondary to ICU Admission by sufficient autophagy inducing compound to inhibit or suppress critical illness enhanced osteoclastogenesis or increased osteoclast differentiation. The methods include administering of an autophagy activating compound to a mammal to: treat or prevent a bone degenerative disorder; slow bone deterioration; restore lost bone; maintain bone mass and/or bone quality or inhibit bone resorption in particularly by inhibiting or reducing a process by which osteoclasts break down bone and release the minerals resulting in a transfer of calcium from bone fluid to the blood. Also described are methods for administering the autophagy activating compound to treat a bone disorder of hyperresorption of bone and/or enhanced activation of osteoclasts. | 03-06-2014 |
Ilse Vlassenbroeck, Sart-Tilman (liege) BE
Patent application number | Description | Published |
---|---|---|
20100280105 | DETECTION OF MAGE-A EXPRESSION - An oligonucleotide, primer or probe comprises the nucleotide sequences of any of SEQ ID NO. 5, 6, 7, 2, 3, 4, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 25. The oligonucleotides are useful for the detection of the methylation status of a gene, in particular the MAGE-A3 gene. The oligonucleotides are useful in primer pairs, kits and methods for determining the methylation status of the MAGE-A3 gene and for diagnosing cancer, directing therapy and selecting subjects for treatment. The primer or probe can comprise a loop or hairpin structure and can be used in real-time methylation specific PCR. | 11-04-2010 |
20110287416 | METHYLATION DETECTION - A real-time method of detecting the presence and/or amount of a methylated or unmethylated gene of interest in a DNA-containing sample, comprises the steps of: (a) contacting the DNA-containing sample with a reagent which selectively modifies unmethylated cytosine residues in the DNA to produce detectable modified residues but which does not modify methylated cytosine residues (b) amplifying at least a portion of the methylated or unmethylated gene of interest using at least one primer pair, at least one primer of which is designed to bind only to the sequence of methylated or unmethylated DNA following treatment with the reagent, wherein at least one primer in the primer pair is a primer containing a step loop structure carrying a donor and an acceptor moiety of a molecular energy transfer pair arranged such that in the absence of amplification, the acceptor moiety quenches fluorescence emitted by the donor moiety upon excitation and during amplification, the stem loop structure is disrupted so as to separate the donor and acceptor moieties sufficiently to produce a detectable fluorescence signal which is detected in real-time to provide an indication of the gene copy number of the methylated or unmethylated gene of interest (c) quantifying the results of the real-time detection against a standard curve for the methylated or unmethylated gene of interest to produce an output of gene copy number. The method may be characterized in that the amplification is considered valid where the cycle threshold value is less than (40). Alternatively the method, which may be carried out in real-time or at end point, is characterized in that the portion of the gene which is amplified is between approximately (50) and 250 bp, especially for plasma and serum samples. | 11-24-2011 |
20130302363 | DETECTION OF MAGE-A EXPRESSION - An oligonucleotide, primer or probe comprises the nucleotide sequences of any of SEQ ID NO. 5, 6, 7, 2, 3, 4, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 25. The oligonucleotides are useful for the detection of the methylation status of a gene, in particular the MAGE-A | 11-14-2013 |
Ilse Zolle, Wien AT
Patent application number | Description | Published |
---|---|---|
20080206138 | Radiolabelled Phenylethyl Imidazole Carboxylic Acid Ester Derivatives - Compounds derived from phenylethyl imidazole carboxylic acid esters have shown selective accumulation of radioactivity in the adrenal cortex, when labeled with a radioactive halogen. In particular, these compounds bind selectively to adrenocortical tissue facilitating the diagnosis of adrenal cortical masses such as incidentaloma, adenoma, primary and metastatic cortical carcinoma. Trace amounts are injected intravenously and accumulate rapidly in the adrenals, maintaining a high radioactivity plateau, which permits external imaging using computed SPECT (single photon emission) or PET (positron emission) techniques. | 08-28-2008 |
20080207916 | Radiolabelled Phenylethyl Imidazole Carboxylic Acid Ester Derivatives - The invention relates to radioactively labeled derivatives of (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid esters, uses, and methods for preparing these compounds. | 08-28-2008 |